The Future of Drug Testing Isn’t a New Test.
It’s a Better System.
Urine testing has long been the standard in workplace drug testing programs—but its real-world detection performance is often assumed, not measured.
What is FluidPath?
FluidPath is a platform dedicated to improving the effectiveness of workplace drug testing programs.
We are not a laboratory, a collection provider, or a test manufacturer—and we are not here to sell testing services. Instead, FluidPath serves as a central hub for data, education, and practical resources designed to help the industry perform better in its efforts to improve real-world detection effectiveness.
By bringing visibility to matrix performance through a system sensitivity lens, highlighting structural barriers, and supporting those involved across the testing ecosystem, FluidPath helps translate insight into action.
This includes not only analysis and thought leadership, but also accessible tools and training that reduce friction, improve consistency, and support better outcomes across the system.
Our mission is simple
To improve workplace safety by increasing visibility into real-world performance, accelerating the shift beyond legacy processes, and enabling more efficient, modern approaches across the workplace drug testing industry.
The Problem:
A System Sensitivity Gap
But detection begins before the laboratory.
System sensitivity reflects how effectively a testing program identifies drug use under real-world conditions, where collection design, donor behavior, and opportunities for circumvention all play a role.
In practice, individuals respond to incentives. When testing environments allow opportunities to avoid detection, donor behavior adapts accordingly.
This dynamic can create meaningful differences in detection outcomes across testing approaches—differences that are rarely visible in standard program reporting.
Without measuring system sensitivity, programs may appear effective—while failing to see what’s really going on…the blind spot.
Key Points
Most programs are evaluated on cost and test results—not real-world detection effectiveness or risk reduction.
Donor behavior adapts to perceived opportunities to avoid detection-and consequence.
Collection conditions directly influence whether drug use is captured.
Detection gaps can exist – without being visible in standard reporting.
The Evidence
When opportunities to avoid detection exist, behavior adapts—and the impact shows up as measurable differences in system sensitivity across real-world testing programs.
CRG comparative data: Real-world program comparisons show significantly higher detection rates with oral fluid across similar populations. Up to 3.3x higher positivity observed in oral fluid.
DOT paired data: Side-by-side testing within the same applicant populations reveals measurable detection gaps under controlled conditions. Same donors, same time – 3.5x higher positivity in oral fluid.
Quest DTI analysis: National datasets across millions of tests reinforce consistent differences in detection across specimen types. Large-scale trends support real-world findings.
We Accept Events And Party Orders!
Give us a call for enquiries and orders
123-456-7890
